ADHD Clinical Trial
— Ad5Official title:
Psychological Treatment Through Internet and Smartphones for Adults With Attention Deficit Hyperactive Disorder (ADHD) - a Randomized Controlled Trial
NCT number | NCT02041884 |
Other study ID # | 2014/333-31 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2014 |
Est. completion date | February 2017 |
Verified date | January 2020 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to further evaluate the treatment for adults with ADHD used in
our previous study (clinicaltrials.gov ID NCT01659164). It will now be converted to therapist
supported, internet-delivered cognitive behavioral therapy (iCBT) with an additional
smartphone application and evaluated through a randomized controlled trial during 12 weeks.
The patients will be randomized to one of three conditions
- an active treatment group where the intervention is based on cognitive - and dialectical
behavioral therapy (CBT and DBT) and the mobile app.
- an active ICBT-treatment based on psychoeducation, a CBT stress-reduction program and
Applied Relaxation, and
- treatment as usual (TAU) / waiting list.
The main objective of the study is to evaluate if both of the treatment conditions will show
better outcomes than TAU regarding decreased ADHD symptoms and increased functioning and life
quality.
Another objective is to evaluate if the group receiving the active iCBT treatment (based on
CBT and DBT) will show better outcomes in comparison to the control group regarding ADHD
symptoms, overall functioning and life quality.
Status | Completed |
Enrollment | 175 |
Est. completion date | February 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Swedish citizen - Clinical diagnosis of AD/HD according to DSM-IV or DSM-5 - Age 18-65 - 17 or more on the Adult ADHD Self Report Scale (ASRS v1.1) - Not medically treated for adhd symptoms, or medically treated with central stimulants or comparable substance since at least one month with no significant changes in dosage and where no change in medical treatment is anticipated during the study time frame for the participant. No change in any other medical treatment is anticipated during the study time frame for the participant. - Participant are by investigators considered able to follow through the training protocol and take part in measures taken during the study time frame - The participant hasn´t used drugs the last 3 months - Access to, and ability to use the Internet and mobile phone during the study time - ability to understand Swedish in speech and writing Exclusion Criteria: - Diagnosed substance abuse according to DSM-IV or DSM-5 criteria within 3 months prior to screening. Earlier episodic substance abuse is not excluding - Co-existing psychiatric condition that investigators believe will unable the participant to follow through the training protocol and take part in measures taken during the study time frame. - IQ =85 according to a neuropsychological assessment - Suicidality risk which is assessed during the first assessment interview. - Organic brain syndrome - Serious somatic condition which will unable the participant to participate (through the training protocol)or, is anticipated to have a negative impact on the treatment results - Autism spectrum disorder where the function level is deemed too low for the treatment to be carried out which is defined as moderate or severe problems scale (level 2 and 3) according to DSM-5 - Severe depression defined by >34 p on MADRS-S or by a clinician´s assessment - Other current psychological treatment for AD/HD or previous participation in such a treatment that is deemed to interfere with the study design - severe writing and reading disabilities - dyslexia of such degree that it impedes participation |
Country | Name | City | State |
---|---|---|---|
Sweden | Internetpsykiatrienheten, Psykiatri Sydväst, SLSO | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet | Stockholm County Council, Sweden |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Treatment evaluation | The investigators design own questions in order to evaluate how the participants have experienced the intervention regarding to knowledge, usage of the treatment methods and possible difficulties that they have experienced during treatment. | during treatment and after 12 weeks of treatment (post) | |
Other | CGI-I | Clinical Global Impression - Improvement scale (rated by a clinician in order to detect level of improvement or worsening due to treatment) | 12 weeks (post) and after 3 and 12 months (post) | |
Other | TCS | Treatment Credibility Scale (self report) | Filled out by the patient at the 1st and 5th week of treatment | |
Other | *CSQ-8 | Client Satisfaction Questionnaire-8 (self report) - in order to evaluate the treatment satisfaction | 12 weeks (post) | |
Primary | Change (from baseline) in ASRS- v 1.1 | ADHD Self Report Scale (ASRS) (self rating) | Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in ADHD Rating Scale | ADHD Rating Scale - assessed by an expert rater blind to Group allocation | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in EQ-5D | Euroqol - (self report) to measure general health and quality of life | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in ISI | Insomnia Severity Index - (self report) to measure insomnia symptoms | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in PSS-4 | Perceived Stress Scale - (self report) to measure level of stress in everyday life | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in SDS | Sheehan Disability Scale - (self report) to measure level of disability in everyday life | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in MADRS-S | Montgomery-Åsberg Depression Rating Scale - (self report) to measure level of depression | Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in DERS | Difficulties of Emotion Regulation Scale - (self report) | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in AaQoL | Adult ADHD Quality of Life Measure - self report | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in SWLS | Satisfaction With Life Scale (self report) - measuring life quality. To evaluate the impact of the intervention on quality of Life, only the first three items in the scale will be used since the last two includes the whole Life-span and not just how Life quality is percived at the moment. | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Change (from baseline) in WAI-1 | Work Ability Index (self report - one item) - a self estimation of working ability | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) | |
Secondary | Changes (from baseline) in CGI-S | Clinical Global Impression - Severity scale - assessed by a blind expert rater - measuring symptom severity | Baseline, 12 weeks (post), 24 weeks (FU3), and after 60 weeks (FU12) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03148782 -
Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
|
N/A | |
Recruiting |
NCT06038942 -
Formal Versus Informal Mindfulness Among University Students With Self-reported ADHD, Nonsuicidal Self-injury, or Stress
|
N/A | |
Not yet recruiting |
NCT06456372 -
Digital Health Intervention for Children With ADHD
|
N/A | |
Completed |
NCT05518435 -
Managing Young People With ADHD in Primary Care Study
|
||
Active, not recruiting |
NCT04978792 -
Does Cultivating Self-compassion Improve Resilience to Criticism and Improve Mental Health in Adults With ADHD?
|
N/A | |
Completed |
NCT03216512 -
Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD
|
N/A | |
Completed |
NCT02900144 -
Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)
|
N/A | |
Completed |
NCT02829528 -
Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention
|
N/A | |
Not yet recruiting |
NCT02906501 -
Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances
|
N/A | |
Terminated |
NCT02271880 -
Improving Medication Adherence in ADHD Adolescents
|
N/A | |
Completed |
NCT02562469 -
ACTIVATE: A Computerized Training Program for Children With ADHD
|
N/A | |
Recruiting |
NCT02255565 -
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
|
Phase 4 | |
Completed |
NCT02463396 -
Mindfulness Training in Adults With ADHD
|
N/A | |
Terminated |
NCT01733680 -
Amiloride Hydrochloride as an Effective Treatment for ADHD
|
Early Phase 1 | |
Completed |
NCT01673594 -
Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist
|
Phase 4 | |
Completed |
NCT02300597 -
Internet-based Support for Young People With ADHD and Autism - a Controlled Study
|
N/A | |
Active, not recruiting |
NCT01137318 -
Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT01404273 -
Functional MRI of Relaxation Response Training in Adults With Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT00573859 -
The Reinforcing Mechanisms of Smoking in Adult ADHD
|
Phase 1/Phase 2 | |
Completed |
NCT00586157 -
Study of Medication Patch to Treat Children Ages 6-12 With ADHD
|
Phase 4 |